Deborah L Tanner Insider Trading $LH LABORATORY CORP OF AMERICA HOLDINGS
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Deborah L Tanner.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Deborah L Tanner. Deborah L Tanner is CEO, Covance Drug Development in LABORATORY CORP OF AMERICA HOLDINGS ($LH) and in WEST PHARMACEUTICAL SERVICES INC ($WST) and Corp. Executive Vice President in COVANCE INC ($CVD) and Corporate Sr. Vice President in COVANCE INC ($CVD).
Deborah L Tanner in LABORATORY CORP OF AMERICA HOLDINGS
Industry: SERVICES-MEDICAL LABORATORIES [8071]
Position of Deborah L Tanner: CEO, Covance Drug Development
Holdings: 19,754 shares
Current Value: $2,565,254
Latest Transaction: Mar 15 2016
$LH Market Capitalization: $13.45B
$LH Previous Close: $129.86
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Deborah L Tanner in LABORATORY CORP OF AMERICA HOLDINGS
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 11,710 | 0 | 18,270 | |
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,220 | 0 | 29,980 | |
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Payment of Exercise | F | 115.49 | 4,213 | 486,559 | 19,754 | 24 K to 19.8 K (-17.58 %) |
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Buy | M | 0.00 | 11,710 | 0 | 23,967 | 12.3 K to 24 K (+95.54 %) |
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Payment of Exercise | F | 115.49 | 374 | 43,193 | 12,257 | 12.6 K to 12.3 K (-2.96 %) |
| Mar 15 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,220 | 0 | 12,632 | 11.4 K to 12.6 K (+10.69 %) |
| Feb 11 2016 | LH | LABORATORY CORP OF ... | Keller Deborah L | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 4,120 | 0 | 31,200 |
Page: 1